Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03459807 · ClinicalTrials.gov registry record · Phase 2
Blood Pressure Lowering in Dialysis (BOLD) Trial
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT03459807 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 50 participants.
The verdict
NCT03459807, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
Blood pressure may be one of the most important modifiable risk factors for cardiovascular disease in patients with end-stage-renal-disease undergoing maintenance hemodialysis. Although a systolic blood pressure \<140 mmHg treatment target has been recommended, there remains uncertainty on which blood pressure should be targeted, more specifically that measured in the dialysis unit or at home. Observational studies have reported a paradoxical U-shaped associated with dialysis unit (pre-dialysis) systolic blood pressure and cardiovascular events and death (where blood pressure below 140 mmHg is actually linked with poor outcomes). Conversely, the same studies have reported a linear association between higher home systolic blood pressure and worse clinical outcomes, where blood pressure below 140 mmHg is associated with better outcomes. This pilot clinical trial aims to address this important question.
Interventions
- DRUG Anti-Hypertensive medications
- PROCEDURE Dry Weight Adjustment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-03-23 |
| Est. Completion | 2018-12-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03459807
The ClinicalTrials.gov registry entry for NCT03459807 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anti-Hypertensive medications is the first listed.
NCT03459807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03459807 about?
NCT03459807 is a clinical study titled "Blood Pressure Lowering in Dialysis (BOLD) Trial". Blood pressure may be one of the most important modifiable risk factors for cardiovascular disease in patients with end-stage-renal-disease undergoing maintenance hemodialysis. Although a systolic blood pressure \<140 mmHg treatment target has been recommended, there remains uncertainty on which blo...
What is the current status of trial NCT03459807?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2018-03-23. Estimated completion is 2018-12-06.
What interventions are being tested in trial NCT03459807?
The interventions under investigation include: Anti-Hypertensive medications (DRUG), Dry Weight Adjustment (PROCEDURE).
Who is sponsoring clinical trial NCT03459807?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.